Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celularity (CELU) Payables (2020 - 2025)

Celularity (CELU) has disclosed Payables for 6 consecutive years, with $28.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 87.47% to $28.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $28.9 million, a 87.47% increase, with the full-year FY2024 number at $27.2 million, up 92.11% from a year prior.
  • Payables was $28.9 million for Q3 2025 at Celularity, up from $24.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $43.4 million in Q4 2022 to a low of $5.2 million in Q1 2021.
  • A 5-year average of $18.0 million and a median of $13.7 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: soared 14989.52% in 2021, then tumbled 68.61% in 2024.
  • Celularity's Payables stood at $9.3 million in 2021, then soared by 365.95% to $43.4 million in 2022, then plummeted by 67.42% to $14.1 million in 2023, then surged by 92.11% to $27.2 million in 2024, then grew by 6.25% to $28.9 million in 2025.
  • Per Business Quant, the three most recent readings for CELU's Payables are $28.9 million (Q3 2025), $24.4 million (Q2 2025), and $23.3 million (Q1 2025).